PharmaIN to Present Promising Interim Data from its Ongoing Phase 1 Trial of PHIN-214, an Optimized Vasopressor for Decompensated Cirrhosis, at The Liver Meeting® 2024

PharmaIN Corporation is set to present promising data from its ongoing Phase 1 trial of PHIN-214, an optimized vasopressor therapy for decompensated cirrhosis, at The Liver Meeting® 2024. BOTHELL, Wash., Oct. 16, 2024 /PRNewswire-PRWeb/ -- PharmaIN Corporation, a clinical-stage...